It's now very clear that tramadol sales will not bring much to the table in terms of cash flow, at least for some time.

The bet is almost entirely on the FDA approval of trazadone and the signing of a marketing & distribution agreement...DDSS is conserving as much cash as possible, by lowering its burn on SG&A, until that occurs.

DDSS probably has 18 to 24 months on cash reserves on its balance sheet...but they (we) will need that FDA approval to remain viable.